LL-37 is a naturally occurring human peptide made of 37 amino acids. It is the only member of the cathelicidin family of antimicrobial peptides found in humans. It is not FDA-approved, and there is no FDA-approved product that contains it.
Its name comes from its first two amino acids, both leucine (L), and its length. The body makes LL-37 by cutting it from a larger precursor protein called hCAP18. It is produced by white blood cells and by cells lining the skin, airways and gut, as part of the innate immune system, the body's first line of defense.
In laboratory studies, LL-37 can kill some bacteria, fungi and viruses, largely by disrupting their outer membranes. It also acts as a signal to immune cells, influencing inflammation and wound repair.
More is not always better. Research has linked excess or altered LL-37 to inflammatory skin diseases. A 2007 study in Nature Medicine tied abnormal cathelicidin processing to the redness and inflammation of rosacea, and a 2007 study in Nature found that LL-37 bound to the body's own DNA can activate immune cells involved in psoriasis.
The best-known human studies tested LL-37 applied directly to chronic leg wounds. In a first-in-human trial published in Wound Repair and Regeneration in 2014, 34 people with hard-to-heal venous leg ulcers received LL-37 or placebo on the wound for 4 weeks. The two lower strengths were linked to faster healing, and no safety concerns were reported.
A larger phase 2b trial of this topical form, called ropocamptide, enrolled 144 patients. In November 2020, its developer, Promore Pharma, reported no statistically significant difference from placebo in the study group as a whole, although patients with larger ulcers did better. No LL-37 product has been approved, and results for a product applied to wounds on the skin do not show what LL-37 does by other routes.
Current status: Not FDA-approved.
The FDA previously placed cathelicidin LL-37 in Category 2 of its compounding lists, the group of bulk substances that raise significant safety risks. The agency said compounded LL-37 may pose a risk of immunogenicity (an unwanted immune response) for certain routes of administration, may have complexities with peptide-related impurities and characterization, and that it lacked enough safety information to know whether the drug would cause harm in humans.
In April 2026 the FDA removed LL-37 from Category 2 because the nomination was withdrawn. That removal does not make it eligible for compounding under section 503A. The FDA has said it intends to consult its Pharmacy Compounding Advisory Committee on LL-37 before the end of February 2027. As of late September 2026, LL-37 was not on the 503A bulks list.
Products sold online as "research chemicals" or labeled "for research purposes only" are not approved medicines, and the FDA has not reviewed their identity, purity or quality.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply, prepare or distribute LL-37 in any form, and nothing on this page should be read as an offer.
If you have questions about LL-37 or a related health concern, talk to a licensed healthcare provider who knows your medical history.
See the full list of compound profiles in the Peptide Guide. Other immune-related peptides in the guide include thymosin alpha-1 and KPV. For the legal background, read whether peptides are legal in the U.S.